Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Foghorn Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was $3.82M. For fiscal 2025 it was -$83.06M. The highest annual figure on record is -$50.39M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$83.06M | – |
| FY2024 | Dec 31, 2024 | -$99.56M | – |
| FY2023 | Dec 31, 2023 | -$104.46M | – |
| FY2022 | Dec 31, 2022 | -$113.82M | – |
| FY2021 | Dec 31, 2021 | -$97.51M | – |
| FY2020 | Dec 31, 2020 | -$67.20M | – |
| FY2019 | Dec 31, 2019 | -$50.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $56.84M | – |
| Q2 FY2026 | Jun 30, 2026 | -$8.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.20M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -$27.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.19M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.47M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.95M | – |
See a number that looks wrong?